The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Everolimus-Eluting versus Paclitaxel-Eluting Stents in Coronary Artery Disease
Open accessAbstract
BACKGROUND: Previous studies have established the superiority of coronary everolimus-eluting stents over paclitaxel-eluting stents with respect to angiographic findings. However, these trials were not powered for superiority in clinical end points. METHODS: We randomly assigned 3687 patients at 66 U.S. sites to receive everolimus-eluting stents or paclitaxel-eluting stents without routine follow-up angiography. The primary end point was the 1-year composite rate of target-lesion failure (defined as cardiac death, target-vessel myocardial infarction, or ischemia-driven target-lesion revascularization). RESULTS: Everolimus-eluting stents were superior to paclitaxel-eluting stents with respect to the primary end point of target-lesion failure (4.2% vs. 6.8%; relative risk, 0.62; 95% confidence interval, 0.46 to 0.82; P=0.001). Everolimus-eluting stents were also superior with respect to the major secondary end point of the 1-year rate of ischemia-driven target-lesion revascularization (P=0.001) and were noninferior with respect to the major secondary end point of the 1-year composite rate of cardiac death or target-vessel myocardial infarction (P<0.001 for noninferiority; P=0.09 for superiority). The 1-year rates of myocardial infarction and stent thrombosis were also lower with everolimus-eluting stents than with paclitaxel-eluting stents (1.9% vs. 3.1%, P=0.02 for myocardial infarction; 0.17% vs. 0.85%, P=0.004 for stent thrombosis). Target-lesion failure was consistently reduced with everolimus-eluting stents as compared with paclitaxel-eluting stents in 12 prespecified subgroups, except in the subgroup of patients with diabetes (6.4% vs. 6.9%, P=0.80). CONCLUSIONS: Everolimus-eluting stents, as compared with paclitaxel-eluting stents, resulted in reduced rates of target-lesion failure at 1 year, results that were consistent in all patients except those with diabetes, in whom the results were nonsignificantly different. (ClinicalTrials.gov number, NCT00307047.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions
Cutlip, D. E., Windecker, S., Mehran, R., Boam, A., Cohen, D. J., van Es, G.-A., Gabriel Steg, P., Morel, M.-A., Mauri, L., Vranckx, P., et al. (2007) · Circulation · doi:10.1161/circulationaha.106.685313 · Cited by 5,497
Self-citationWRITING COMMITTEE MEMBERS, Smith, S. C., Feldman, T. E., Hirshfeld, J. W., Jacobs, A. K., Kern, M. J., King, S. B., Morrison, D. A., O’Neill, W. W., Schaff, H. V., et al. (2006) · Circulation · doi:10.1161/circulationaha.105.170815 · Cited by 2,218
Safety and Efficacy of Sirolimus- and Paclitaxel-Eluting Coronary Stents
Stone, G. W., Moses, J. W., Ellis, S. G., Schofer, J., Dawkins, K. D., Morice, M.-C., Colombo, A., Schampaert, E., Grube, E., Kirtane, A. J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067193 · Cited by 1,631
Self-citationKing, S. B., Smith, S. C., Hirshfeld, J. W., Jacobs, A. K., Morrison, D. A., Williams, D. O., 2005 WRITING COMMITTEE MEMBERS, Smith, S. C., Feldman, T. E., Hirshfeld, J. W., et al. (2008) · Circulation · doi:10.1161/circulationaha.107.188208 · Cited by 1,014
Clopidogrel Use and Long-term Clinical Outcomes After Drug-Eluting Stent Implantation
Eisenstein, E. L., Anstrom, K. J., Kong, D. F., Shaw, L. K., Tuttle, R. H., Mark, D. B., Kramer, J. M., Harrington, R. A., Matchar, D. B., Kandzari, D. E., et al. (2007) · JAMA · doi:10.1001/jama.297.2.joc60179 · Cited by 870
A Pooled Analysis of Data Comparing Sirolimus-Eluting Stents with Bare-Metal Stents
Spaulding, C., Daemen, J., Boersma, E., Cutlip, D. E., & Serruys, P. W. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066633 · Cited by 704
Self-citationKedhi, E., Joesoef, K. S., McFadden, E., Wassing, J., van Mieghem, C., Goedhart, D., & Smits, P. C. (2010) · The Lancet · doi:10.1016/s0140-6736(09)62127-9 · Cited by 687
Endothelial Cell Recovery Between Comparator Polymer-Based Drug-Eluting Stents
Joner, M., Nakazawa, G., Finn, A. V., Quee, S. C., Coleman, L., Acampado, E., Wilson, P. S., Skorija, K., Cheng, Q., Xu, X., et al. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.04.030 · Cited by 641
Stone, G. W. (2008) · JAMA · doi:10.1001/jama.299.16.1903 · Cited by 582
Self-citationKirtane, A. J., Gupta, A., Iyengar, S., Moses, J. W., Leon, M. B., Applegate, R., Brodie, B., Hannan, E., Harjai, K., Jensen, L. O., et al. (2009) · Circulation · doi:10.1161/circulationaha.108.826479 · Cited by 577
Self-citationAiroldi, F., Colombo, A., Morici, N., Latib, A., Cosgrave, J., Buellesfeld, L., Bonizzoni, E., Carlino, M., Gerckens, U., Godino, C., et al. (2007) · Circulation · doi:10.1161/circulationaha.106.686048 · Cited by 455
Serruys, P. W. J. C., Ruygrok, P., Neuzner, J., Piek, J. J., Seth, A., Schofer, J. J., Richardt, G., Wiemer, M., Carrié, D., Thuesen, L., et al. (2006) · PubMed · Cited by 346
Stettler, C., Allemann, S., Wandel, S., Kastrati, A., Morice, M. C., Schomig, A., Pfisterer, M. E., Stone, G. W., Leon, M. B., Lezo, J. S. D., et al. (2008) · BMJ · doi:10.1136/bmj.a1331 · Cited by 320
Self-citationStone, G. W., Ellis, S. G., Colombo, A., Dawkins, K. D., Grube, E., Cutlip, D. E., Friedman, M., Baim, D. S., & Koglin, J. (2007) · Circulation · doi:10.1161/circulationaha.106.687186 · Cited by 181
Self-citationImpact of Routine Angiographic Follow-Up on the Clinical Benefits of Paclitaxel-Eluting Stents
Pinto, D. S., Stone, G. W., Ellis, S. G., Cox, D. A., Hermiller, J. B., O’Shaughnessy, C. D., Mann, J. T., Mehran, R., Na, Y., Turco, M. A., et al. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.02.060 · Cited by 140
Self-citationDaemen, J., Garcia-Garcia, H. M., Kukreja, N., et al. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehl412 · Cited by 108
Paclitaxel-Eluting Coronary Stents in Patients With Diabetes Mellitus
Kirtane, A. J., Ellis, S. G., Dawkins, K. D., Colombo, A., Grube, E., Popma, J. J., Fahy, M. P., Leon, M. B., Moses, J. W., Mehran, R., et al. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.10.035 · Cited by 107
Self-citationDifferential phosphoinositide 3-kinase signaling: implications for PTCA?
Ročić, P. (2009) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00952.2009 · Cited by 11
Cited by
2018 ESC/EACTS guidelines on myocardial revascularization
Neumann, F.-J., Sousa-Uva, M., Ahlsson, A., Alfonso, F., Banning, A. P., Benedetto, U., Byrne, R. A., Collet, J.-P., Falk, V., Head, S. J., et al. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehy394 · Cited by 7,167
(2014) · European Heart Journal · doi:10.1093/eurheartj/ehu278 · Cited by 4,314
2014 ESC/EACTS Guidelines on myocardial revascularization
Kolh, P., Windecker, S., Alfonso, F., Collet, J.-P., Cremer, J., Falk, V., Filippatos, G., Hamm, C., Head, S. J., Jüni, P., et al. (2014) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezu366 · Cited by 4,199
Writing Committee Members, Levine, G. N., Bates, E. R., Blankenship, J. C., Bailey, S. R., Bittl, J. A., Cercek, B., Chambers, C. E., Ellis, S. G., Guyton, R. A., et al. (2011) · Circulation · doi:10.1161/cir.0b013e31823ba622 · Cited by 3,289
Developed with the special contribution of the European Association for Percutaneous Cardiovascular Interventions (EAPCI), Authors/Task Force Members, Wijns, W., Kolh, P., Danchin, N., Di Mario, C., Falk, V., Folliguet, T., Garg, S., Huber, K., et al. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq277 · Cited by 3,184
Metadata
- Authors
- Stone, G. W., Rizvi, A., Newman, W., Mastali, K., Wang, J. C., Caputo, R., Doostzadeh, J., Cao, S., Simonton, C. A., Sudhir, K., Lansky, A. J., Cutlip, D. E., & Kereiakes, D. J.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2010-05-06
- Volume
- 362
- Issue
- 18
- Pages
- 1663-1674
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2009589924
- Cited by
- 902
- References
- 19
- FWCI
- 114.89
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.